164 results on '"Frankova, Sona"'
Search Results
2. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
3. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
4. Alcohol consumption and liver phenotype of individuals with alpha‐1 antitrypsin deficiency.
5. Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
6. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
7. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence
8. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
9. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study
10. Alpha-1 antitrypsin (AAT) augmentation and the liver phenotype of adults with AAT deficiency (genotype Pi*ZZ)
11. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver disease
12. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
13. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
14. The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure
15. Impact of alcohol consumption on the liver phenotype in alpha-1 antitrypsin deficiency
16. Transient Elastography as the First-Line Assessment of Liver Fibrosis and Its Correlation with Serum Markers
17. Transjugular Intrahepatic Portosystemic Shunt in Liver Transplant Recipients: Outcomes in Six Adult Patients
18. Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma
19. Preemptive treatment with glecaprevir and pibrentasvir prevents HCV transmission from HCV viraemic donors to solid organ transplant recipients (single centre experience)
20. PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes
21. Predictors of Significant Liver Fibrosis in People with Chronic Hepatitis C Who Inject Drugs in the Czech Republic.
22. WED-135-YI Impact of metabolic alterations on liver phenotype of patients with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ)
23. TOP-141 Longitudinal assessment of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype) provides evidence for clinical patient management
24. OS-041-YI A spatiotemporal map of the hepatocyte proteome in alpha-1 antitrypsin deficiency by single-cell and visual proteomics
25. HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons
26. Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma.
27. Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk
28. Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis
29. Risk factors of incidental hepatocellular carcinoma occurrence: single-centre experience: P-631
30. Is elimination of HCV in 2030 realistic in Central Europe
31. Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis
32. THU-164 - The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure
33. THU-281 - Impact of alcohol consumption on the liver phenotype in alpha-1 antitrypsin deficiency
34. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
35. How close are we to hepatitis C virus elimination in Central Europe?
36. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age
37. IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post‐prophylaxis and late period
38. Sa1357 – Pancreatic Cancer in Liver Transplant Recipients
39. Aquaporin-2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality
40. Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort
41. Aquaporin-2 excretion in hospitalized patients with cirrhosis:Relation to development of renal insufficiency and mortality
42. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
43. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
44. Aquaporin‐2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality
45. Risk of Late-Onset CMV Infection After Liver Transplantation is Associated with Recipient's IFNL4 RS12979860 Genotype
46. Pancreatic cancer in liver transplant recipients
47. Sa1600 Treatment of Uncontrollable Acute Variceal Bleeding With Self-Expanding Metal Stent: A Single Center Experience
48. USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
49. USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
50. Sa1007 Assessment of Liver Stiffness by Shear Wave Elastography in Liver Transplant Recipients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.